DIAZOLE LACTAMS Russian patent published in 2018 - IPC C07D401/14 C07D403/14 C07D405/14 C07D487/04 A61K31/4178 A61K31/4155 A61K31/4192 A61K31/4196 

FIELD: chemistry.

SUBSTANCE: described are compounds of formula I, where n is an integer from 0 to 3; each A is independently selected from the group consisting of N and CH; A¹ represents N or C(R⁵); A² represents N or C(R⁷); R¹ and R² each are independently selected from the group consisting of H, halogen and -OR^a; R³ is a representative selected from the group consisting of H, C_1-8 alkyl, C_3-8 cycloalkyl, C_2-8 alkenyl, C_1-8 haloalkyl, -OR^a, -NR^aR^b, phenyl and 5- or 6- member heteroaryl; R⁴ is a representative selected from the group consisting of H and C_1-8 alkyl; R⁵, R⁶, R⁷ and R⁸ each are independently selected from the group consisting of H, halogen, C_1-8 alkyl, C_1-8 haloalkyl, C_1-8 hydroxyalkyl abd 5- or 6- member heteroaryl; R⁹ is a representative selected from the group consisting of H and C_1-8 alkyl; and each R^a and R^b are independently selected from the group consisting of hydrogen atom, C_1-8 alkyl; where each heteroaryl has from one to five heteroatoms selected from the group consisting of N, O and S, or their pharmaceutically acceptable salts. Said compounds act as potential CCR1 receptor antagonists and have in vivo anti-inflammatory action. Also, the pharmaceutical composition comprising the compound of formula I is described, as well as the method for treating diseases by administering the compound of formula I. formula I.

EFFECT: diazole lactams are proposed.

28 cl, 2 tbl, 46 ex